Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients

People of East Asian ethnicity have a different prevalence of and show unique clinical characteristics and tumor histology of oncogenic mutations. However, only limited studies have explored the landscape of genomic alterations in lung adenocarcinoma derived from Asian patients thus far. In this single‐center study, with an aim to elucidate the mutational profile of lung cancer in people of Chinese ethnicity and to use the obtained information to guide decision‐making for treatment, we employed a well‐validated assay to perform comprehensive genomic characterization of tumor specimens from 306 Chinese lung cancer patients. A total of 845 individual genomic alterations were found in 145 tumor‐related genes with a median of 2.8 alterations (range: 1–18) per sample. The most frequently mutated genes were EGFR (46.7%), TP53 (21.2%), ALK (12.1%; 8.8% of mutation and 3.3% of rearrangement) and KRAS (10.1%). Upon comparison with the Cancer Genome Atlas dataset, we found that EGFR was mutated at a much higher frequency in our cohort than in Caucasians, whereas KRAS was only found in 10.1% of our Chinese patients. Clinically relevant genomic alterations were identified in 185 (60.5%) patients, including 50% in adenocarcinoma patients and 14% in squamous cell carcinoma patients. Our findings suggest that the Asian ethnicity is significantly different from the Caucasian ethnicity with regard to the presence of somatic driver mutations. Furthermore, we showed that the use of a comprehensive genotyping approach could help identify actionable genomic alterations that have potential impact on therapeutic decisions.

[1]  Yi-long Wu,et al.  Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  G. Giaccone,et al.  Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  P. Jänne,et al.  The quest to overcome resistance to EGFR-targeted therapies in cancer , 2013, Nature Medicine.

[4]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[5]  S. Thongprasert,et al.  A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[7]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[8]  P. Stephens,et al.  Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. , 2016, The oncologist.

[9]  Jae Cheol Lee,et al.  Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer , 2013, BMC Cancer.

[10]  Linghua Wang,et al.  Genomic sequencing for cancer diagnosis and therapy. , 2014, Annual review of medicine.

[11]  Adam J. Yen,et al.  Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer , 2014, Oncotarget.

[12]  R. Herbst,et al.  Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Tan,et al.  The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. , 2004, Chest.

[14]  Nikhil Wagle,et al.  High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.

[15]  Robert Brian Jenkins,et al.  Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  Jean Mosser,et al.  Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) , 2016, The Lancet.

[17]  Di Shao,et al.  A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma , 2016, Scientific Reports.

[18]  J. Barretina,et al.  Genomic medicine frontier in human solid tumors: prospects and challenges. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  I. Umelo,et al.  Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. , 2012, Lung cancer.

[20]  G. Giaccone,et al.  Refining the treatment of NSCLC according to histological and molecular subtypes , 2015, Nature Reviews Clinical Oncology.

[21]  I. Wistuba,et al.  The evolving genomic classification of lung cancer , 2013, The Journal of pathology.

[22]  De Grèvea,et al.  linical activity of afatinib ( BIBW 2992 ) in patients with lung adenocarcinoma ith mutations in the kinase domain of HER 2 / neu , 2012 .

[23]  J. O’Shaughnessy,et al.  BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. , 2014, Lung cancer.

[24]  M. Ladanyi,et al.  Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches , 2015, Clinical Cancer Research.

[25]  Richard Bourgon,et al.  High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing , 2014, Clinical Cancer Research.

[26]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[27]  H. Ji,et al.  Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  L. Crinò,et al.  Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  Tae Min Kim,et al.  Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[30]  Yi-long Wu,et al.  Emerging paradigms in targeted treatments for Asian patients with NSCLC , 2015, Expert opinion on pharmacotherapy.

[31]  Funda Meric-Bernstam,et al.  Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Marilyn M. Li,et al.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[33]  R. Yelensky,et al.  Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. , 2016, Cancer research.

[34]  N. Peled,et al.  Clinical Impact of Hybrid Capture–Based Next‐Generation Sequencing on Changes in Treatment Decisions in Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[36]  S. Peters,et al.  Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.

[38]  Robert L Schmidt,et al.  Multi-Institutional Evaluation of Inter-rater Agreement of Variant Classification Based on the 2017 AMP, ASCO and CAP Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. , 2019, The Journal of molecular diagnostics : JMD.

[39]  M. Ladanyi,et al.  Characteristics of Lung Cancers Harboring NRAS Mutations , 2013, Clinical Cancer Research.

[40]  J. Yokota,et al.  Gene aberrations for precision medicine against lung adenocarcinoma , 2016, Cancer science.

[41]  Renato Martins,et al.  Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. , 2014, The Journal of molecular diagnostics : JMD.